Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Basit Öğe Kaydı
dc.authorid0000-0001-9962-8882
dc.authorid0000-0002-3285-417X
dc.authorid0000-0003-4304-9245
dc.authorid0000-0003-1864-0316
dc.authorid0000-0003-3312-8476
dc.authorid0000-0003-2131-2866
dc.authorid0000-0003-0825-1851
dc.authorscopusid56545735000
dc.authorscopusid24471549000
dc.authorscopusid6602557128
dc.authorscopusid57189243089
dc.authorscopusid56370690600
dc.authorscopusid14022986200
dc.authorscopusid55672209100
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.authorwosidBaşcı, Semih/AAB-4823-2021
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.contributor.authorBaşcı, Semih
dc.contributor.authorAta, Naim
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorYigenoğlu, Tuğçe Nur
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorBirinci, Şuayip
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:39:59Z
dc.date.available2022-05-11T14:39:59Z
dc.date.issued2020
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 patients without cancer at a 3/1 ratio (n = 48), diagnosed between March 11, 2020 and May 22, 2020 and included in the Republic of Turkey, Ministry of Health database, were analyzed retrospectively. Results The rates of intensive care unit (ICU) admission, and mechanical ventilation (MV) support were lower in CML patients compared to the control group, however, these differences did not achieve statistical significance (p = 0.1, and p = 0.2, respectively). The length of hospital stay was shorter in CML patients compared with the control group; however, it was not statistically significant (p = 0.8). The case fatality rate (CFR) in COVID-19 patients with CML was 6.3%, and it was 12.8% in the control group. Although the CFR in CML patients with COVID-19 was lower compared to the control group, this difference did not achieve statistical significance (p = 0.5). When CML patients were divided into 3 groups according to the TKI, no significant difference was observed regarding the rate of ICU admission, MV support, CFR, the length of stay in both hospital and ICU (all p > 0.05). Conclusion This study highlights that large scale prospective and randomized studies should be conducted in order to investigate the role of TKIs in the treatment of COVID-19.
dc.identifier.doi10.1177/1078155220953198
dc.identifier.endpage1682
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue7en_US
dc.identifier.pmid32854573
dc.identifier.scopus2-s2.0-85089986029
dc.identifier.scopusqualityQ3
dc.identifier.startpage1676
dc.identifier.urihttps://doi.org/10.1177/1078155220953198
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8819
dc.identifier.volume26
dc.identifier.wosWOS:000563664500001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofJournal of Oncology Pharmacy Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTyrosine kinase inhibitors
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectchronic myeloid leukemia
dc.subjectRespiratory Syndrome Coronavirus
dc.subjectImatinib
dc.subjectAbl
dc.subjectNilotinib
dc.titleOutcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8819.pdf
Boyut:
255.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu